Following intensive research and development, Mirai Medical was formed from a team with over 50 combined years of experience in the areas of pulsed electrical fields, electroporation for cancer, immunotherapy and medical device development to address critical unmet challenges in cancer treatment.

Our ePORE^® technology is a unique  precision therapy platform that targets tumour tissue whilst preserving surrounding healthy tissue structure. Proven to be a safe, simple and cost effective technique, it greatly reduces side effects and improves the experience of cancer patients. It is minimally invasive and allows for faster treatment delivered as a day-case procedure. Through the ideation, designing and manufacturing our technology, clinical evidence has guided everything we do. We believe that in doing this, safety and efficacy will be an intrinsic part of our technology’s promise for patients.

Recent Milestones: Completion of Mirai Pulsed Field Ablation Preclinical Colorectal Porcine Study at Mayo Clinic Publication of EndoVE 21 Patient Colorectal Study at University of Copenhagen Dave Pierce past President Endoscopy at Boston Scientific joins the Mirai Medical board EU and US patent granted on Mirai ePORE Pulse field ablation generator along with key claims Closed bridge round €4m in Q4 2023
Upcoming Milestones: PULSAR Study at Kings Hospital London – Pulse Field Ablation in Complex Polyps Digestive Disease Week Presentation by Mayo Clinic on Mirai Pulse Field Ablation in the Gastrointestinal tract FDA 510k Submission for Mirai Pulse Field Ablation Technology Series A €20M to support US market entry
Products: CE & TSA Approved ePORE® Pulse Field Ablation Generator and disposable catheter for GI EndoVE® and Skin CUTIS devices Investors: Irish Medtech Syndicates; Enterprise Ireland; Western Development Commission Non-Dilutive Grants: DTIF 2021 €7.1m
Company details www.Mirai-Medical.com Mirai Medical, Howley Court, Dublin Road, Oranmore, Galway, Ireland H91 P5PH Declan Soden CEO declan@mirai-medical.com